Takeda and Dr Reddy's partner to launch QDENGA dengue vaccine in India's private sector
India's health regulator approved the QDENGA dengue vaccine for ages 4 to 60, and Dr Reddy’s will market it privately while Takeda handles the public side.
In July 2026, India's Central Drugs Standard Control Organization approved QDENGA, a live-attenuated tetravalent dengue vaccine, for individuals aged 4 to 60. The vaccine, known as TAK-003, uses a DENV-2 backbone with proteins from the other three serotypes and is administered in two doses spaced three months apart. Under a new agreement, Dr Reddy’s Laboratories will handle promotion and distribution of QDENGA in the private market for both pediatric and adult patients, while Takeda will continue to manage public-sector supply.
The companies plan to engage healthcare professionals and boost dengue awareness during the private-market launch. Takeda highlighted its global Phase 3 TIDES study involving over 60,000 participants, showing sustained efficacy across all serotypes. The partnership aims to address India's rising dengue burden, where cases have risen sharply over the past two decades.
Why it matters
Introducing the first approved dengue vaccine in India could reduce the country's growing dengue disease burden.
In this story
